- Home
- FUSE vs QTTB Comparison
FUSE vs QTTB Comparison
Compare FUSE & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FUSE | QTTB |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.2M | 44.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FUSE | QTTB |
|---|---|---|
| Price | $1.73 | $3.52 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | ★ 10.9M | 179.9K |
| Earning Date | 06-05-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,949,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.87 | N/A |
| 52 Week Low | $1.45 | $1.35 |
| 52 Week High | $25.00 | $6.37 |
Technical Indicators
Market Signals| Indicator | FUSE | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 45.91 | 44.58 |
| Support Level | $1.65 | $3.77 |
| Resistance Level | $2.13 | $4.70 |
| Average True Range (ATR) | 0.35 | 0.40 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 6.84 | 11.72 |
Price Performance
Historical ComparisonAbout FUSE Fusemachines Inc.
Fusemachines Inc is a provider of enterprise AI products and solutions. The company provides good quality AI education in underserved communities and helping organizations achieve their full potential with AI. The products of the company include AI Studio, Answer Gen, GenAI Engines, and others.
About QTTB Q32 Bio Inc.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.